RFA-CA-27-016: The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
Sponsor: NCIInternal Deadline: 06/22/2026Institutional Submission Limit: 1Sponsor Deadline: 06/30/2026Program Website
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network.
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.
Submission Process
Limited submissions MUST be coordinated with the Office of the Vice President for Research.
If interested in applying for this opportunity, please combine the following items into a single PDF and email to resdev@mailbox.sc.edu by 5pm on the INTERNAL DEADLINE above:
- Cover page with grant program name & number (if applicable) to which you are applying, your project title, PI (name, department/unit, & email), and list of co-PIs/key collaborators (name & department/unit)
- a two-page project abstract addressing key components/criteria for this specific grant program
- a 2-3 page CV/biosketch for the PI (SCiENcv preferred)